Clinical trial
An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects With Overactive Bladder (OAB)
NCT01655069 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects With Overactive Bladder (OAB)
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 4, 2012
- Completion date
- October 8, 2014
- Enrollment
- 148 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.